TherapeuticsMD, Inc. (TXMD)

Name: TherapeuticsMD, Inc. (TXMD) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0000025743 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Incorporated NV
Fiscal year ends Dec 31

For the year ended 2025-12-31, TherapeuticsMD, Inc. reported revenue of $3.02M. Revenue grew 71.6% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $3.27M.

Key ratios (year ended 2025-12-31)

-145.3%

Operating margin

-18.8%

Net margin

-2.1%

Return on year-end equity

71.6%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 10-Q (quarterly report) · 2026-08-11

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$3.27M	$3.02M	$1.76M	$1.30M	$69.96M	$2.57M	$64.87M	$49.65M	$16.10M	$16.78M	$19.36M
Cost of Revenue	n/a	n/a	n/a	n/a	$1.40M	$1.40M	$15.97M	$6.33M	$2.74M	$2.64M	$4.19M
Gross Profit	n/a	n/a	n/a	$1.30M	$68.57M	$1.17M	$48.90M	$43.31M	$13.36M	$14.14M	$15.17M
R&D Expense	n/a	n/a	n/a	n/a	n/a	$7.09M	$10.43M	$19.79M	$27.30M	$33.85M	$53.94M
Operating Income	-$3.95M	-$4.39M	-$6.11M	-$8.52M	$1.19M	-$79.58M	-$155.54M	-$151.21M	-$130.22M	-$77.63M	-$90.25M
Depreciation & Amortization	$382.0K	$384.0K	$509.0K	$922.0K	$1.19M	$736.0K	$4.07M	$1.39M	$293.9K	$213.1K	$132.5K
EBITDA	-$3.57M	-$4.01M	-$5.60M	-$7.60M	$2.38M	-$78.84M	-$151.47M	-$149.81M	-$129.93M	-$77.42M	-$90.12M
Net Income	-$217.0K	-$569.0K	-$2.18M	-$10.28M	$112.00M	-$172.41M	-$183.52M	-$176.15M	-$132.62M	-$76.93M	-$89.88M
EPS (Diluted)	n/a	-$0.05	-$0.19	-$0.99	$11.96	-$21.66	n/a	n/a	n/a	n/a	n/a
Total Assets	$37.53M	$37.66M	$38.82M	$43.31M	$90.46M	$169.47M	$181.61M	$265.99M	$211.98M	$143.23M	$142.47M
Total Liabilities	$10.40M	$10.78M	$11.45M	$14.02M	$55.31M	$263.09M	$305.61M	$256.78M	$114.46M	$13.32M	n/a
Long-Term Debt	n/a	n/a	n/a	n/a	n/a	$188.27M	$237.70M	n/a	n/a	n/a	n/a
Shareholders' Equity	$27.13M	$26.88M	$27.37M	$29.29M	$35.14M	-$93.62M	-$124.00M	$9.20M	$97.52M	$129.91M	$127.49M
Cash & Equivalents	n/a	n/a	$5.06M	$4.33M	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating Cash Flow	$3.10M	$2.45M	$1.17M	-$23.08M	$9.36M	-$55.13M	n/a	n/a	n/a	n/a	n/a
Capital Expenditures	n/a	n/a	n/a	n/a	n/a	$34.0K	$207.0K	$2.45M	$217.0K	$61.8K	$396.2K
Free Cash Flow	n/a	n/a	n/a	n/a	n/a	-$55.17M	n/a	n/a	n/a	n/a	n/a
Shares Outstanding	11.57M	11.57M	11.53M	11.53M	9.50M	8.60M	299.76M	271.18M	240.46M	216.43M	196.69M
Weighted Average Diluted Shares	n/a	11.57M	11.53M	10.44M	9.37M	7.96M	n/a	n/a	n/a	n/a	n/a
EPS (Basic)	n/a	-$0.05	-$0.19	-$0.99	$12.41	-$21.66	n/a	n/a	n/a	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView